Form 4: Apellis Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 1,599 shares of common stock on January 13, 2025, to cover tax withholding on restricted stock units.
Summary
- On January 13, 2025, Mark Jeffrey DeLong, the Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 1,599 shares of the company's common stock.
- The shares were sold at a price of $28.7021 per share.
- This transaction was executed to cover tax withholding obligations related to the release of restricted stock units on January 10, 2025.
- Following the transaction, DeLong directly owns 58,796 shares of Apellis Pharmaceuticals.
Sentiment
Score: 5
Explanation: This is a neutral event. An executive selling shares to cover taxes is a normal occurrence and doesn't necessarily indicate a positive or negative outlook on the company.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Restricted Stock Units released |
| 01/13/2025 | Date of stock sale transaction |
| 01/14/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.